Head and Neck Cancer
Practical Radiation Oncology
PRO 02 (Live SA-CME) - PRO - Head and Neck Cancer (HPV + ve)
10/20/2018
10:30 AM - 12:00 PM
Location: Room 304
Session Type: Educational
1.50 AMA PRA Category 1 Credits™
1.50 CAMPEP Credits
1.50 MDCB Credits
This event is ticketed and requires separate registration and an additional fee. Space is limited, so please register early. Please note that events and fees are subject to change.
This session will discuss optimal evaluation and treatment of patients with HPV-positive oropharynx cancer. In January 2018, AJCC 8 became the new staging system, with profound differences for HPV-positive oropharynx cancers; the new staging and its implications will be discussed. The session will review the best practices for patient evaluation and evidence-based (and guideline-based) management of HPV-positive cancers in 2018. The expected prognosis and toxicity patterns will be reviewed, in addition to their management. As well, current clinical trials looking at treatment de-escalation strategies will be reviewed, with recommendations on what should be incorporated into practice now on- and off-protocol. The indications for chemoradiation versus radiation alone, the optimal treatment in the postoperative setting after transoral robotic surgery (TORS) and contouring recommendations will be discussed with an emphasis on maximizing outcomes and reducing treatment related toxicity. Didactic information will be strengthened with case-based discussions and vignettes to illustrate real-world implications of these decisions and recommendations.
Learning Objectives:
- Apply AJCC 8 staging to a newly diagnosed patient with HPV-positive oropharynx cancer and determine optimal evaluation and testing prior to treatment.
- Determine appropriate treatment paradigms using evidence-based management for patients with HPV-positive cancers and create detailed treatment plans for individual patients based on particular information about the case.
- Predict and ameliorate treatment-related toxicity for patients undergoing curative treatment for HPV-positive oropharynx cancers, by applying appropriate de-escalation strategies through the use of systemic therapies, surgery and contouring.
Presentations:
10:30 AM - 10:55 AM
Overview of HPV-positive Head and Neck Cancer, Staging Updates, and ASTRO Guideline Review
Speaker: – Stanford University
10:55 AM - 11:20 AM
Strategies for Toxicity Reduction
Speaker: – University of California, San Francisco
11:20 AM - 11:45 AM
Case Discussion
Speaker: – GenesisCare St. Vincent's Hospital
